Every 8-K that CONMED Corporation (CNMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CNMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNMD filings page.
CONMED Corporation reported second quarter 2026 results with net sales of $343.5 million, up 0.3% year-over-year as reported and down 0.5% on a constant currency basis. Excluding exited gastroenterology products, organic constant currency net sales grew 6.0%, with domestic organic sales up 2.5% and international organic constant currency sales up 9.9%.
GAAP diluted EPS was $0.77, up 11.6%, and adjusted diluted EPS was $1.38, up 20.0%, both including a $0.21 benefit from IEEPA tariff refunds. Gross margin improved to 57.5%, and adjusted gross margin to 59.5%. For 2026, CONMED now guides GAAP net sales to $1,358–$1,373 million and adjusted diluted EPS to $4.48–$4.60, with organic constant currency net sales growth of 5.0–6.0%. The company highlighted completion of GI portfolio exits, debt refinancing, expanded indications for the AirSeal Robotic Solution, and recent Board and CFO appointments.
CONMED Corporation has appointed John E. Gallagher as Executive Vice President and Chief Financial Officer, effective July 15, 2026. He will also serve as principal financial and principal accounting officer, succeeding prior CFO leadership while former CFO Todd Garner remains in an advisory role through November 2, 2026.
Gallagher brings nearly three decades of finance experience from Certara, Cue Health, Becton Dickinson, General Electric and Ford. His compensation includes a $650,000 base salary, a target annual bonus at 85% of salary, equity grants under CONMED’s 2025 Long-Term Incentive Plan and a make-whole RSU award.
The agreement provides severance protection under the Executive Severance Plan, with higher cash multipliers and benefits if termination without cause or resignation for good reason occurs within two years after a change in control. Interim finance leaders Patrick Beyer and Kimberly Lockwood revert to their prior roles once Gallagher starts.
CONMED Corporation entered into separate, privately negotiated purchase agreements to repurchase approximately $645.2 million aggregate principal amount of its 2.25% Convertible Senior Notes due 2027 for about $637.2 million in cash.
The purchases from existing noteholders are expected to close on June 15, 2026, subject to customary closing conditions.
CONMED Corporation entered into a First Omnibus Amendment to its existing credit documents to add a new $450 million senior secured delayed draw Term A-2 Loan Facility. This facility is available in a single draw through June 14, 2026 and matures on June 10, 2030, matching CONMED’s existing revolving and term loans.
The company plans to use the Term A-2 proceeds to repurchase a portion of its outstanding 2.25% Convertible Senior Notes due 2026 and to pay related fees and expenses. Interest on the new loans will be based on adjusted term SOFR plus a margin of 1.125%–2.25% or a base rate plus 0.125%–1.25%, tied to CONMED’s consolidated senior secured leverage ratio, with initial margins of 1.75% for SOFR loans and 0.75% for base rate loans.
CONMED Corporation reports several governance updates. The board will expand to nine directors and has appointed Celine Martin and Jeff Mirviss as independent directors effective July 1, 2026, with committee assignments across audit, strategy, compensation, and governance. The board also named Kimberly Lockwood interim Corporate Controller and interim Principal Accounting Officer effective June 1, 2026.
Amended and restated bylaws update advance notice rules, including a 90–120 day window for 2027 annual meeting nominations and proposals, with notices due between January 18 and February 17, 2027. At the May 18, 2026 annual meeting, stockholders elected seven directors, approved the advisory vote on executive compensation, and ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026.
CONMED Corporation reported first quarter 2026 net sales of $317.0 million, down 1.3% year-over-year, as the exit of certain gastroenterology products reduced sales by $15.5 million. Domestic revenue fell 5.8%, while international revenue grew 4.7% as reported.
GAAP diluted earnings per share rose to $0.45 from $0.19 a year earlier, and adjusted diluted EPS was $0.89 versus $0.95. EBITDA was $44.3 million and adjusted EBITDA was $56.4 million, compared to $61.3 million in 2025.
Management raised its 2026 outlook for organic constant currency revenue growth to 5.0%–6.5% and now expects full-year reported revenue of $1.350 billion to $1.375 billion, while reaffirming adjusted diluted EPS guidance of $4.30 to $4.45.
CONMED Corporation reported that Andrew Moller, age 51, will become Interim Principal Financial Officer effective March 15, 2026. He currently serves as Vice President, Corporate Controller and has been the Company’s Principal Accounting Officer since April 2025.
Before joining CONMED in January 2025, Moller held senior finance roles at Smith & Nephew, including Global Controller and CFO Asia-Pacific, and previously worked at Stanley Black & Decker. The company states there are no related-party transactions or family relationships involving Moller and its directors, and his compensation arrangements are unchanged with this interim appointment.
CONMED Corporation filed a current report to let investors know it has released its financial results for the fourth quarter ended December 31, 2025. The company issued a press release on January 28, 2026, and attached it as Exhibit 99.1 to this report.
The filing clarifies that the earnings information in Item 2.02 and the press release are being furnished, not filed, which affects how they are treated under securities laws and how they may be incorporated into other regulatory documents.
CONMED Corporation is sharing an investor presentation as part of its appearance at the J.P. Morgan Healthcare Conference on January 12, 2026. The presentation, furnished as Exhibit 99.1, includes the company’s preliminary 2026 financial guidance and is available on its website in the Investors section under News & Events – Presentations.
The information in this report and the attached presentation is being furnished rather than filed under U.S. securities laws, which means it is not automatically subject to certain liability provisions or incorporated into other filings unless specifically referenced.
CONMED Corporation reported a planned transition of its Chief Financial Officer, Todd Garner. His separation as CFO will be effective on the earlier of March 15, 2026 or the appointment of a new permanent CFO, while he remains employed through November 2, 2026 to support a smooth transition. The company has engaged an executive search firm and begun a comprehensive search for the next CFO.
Garner will receive severance benefits under the company’s Executive Severance Plan in connection with a Qualifying Termination, and will continue to receive his current compensation, benefits, and eligibility for his 2025 annual bonus during the transition period, but will not receive a 2026 annual equity award grant. During the subsequent consulting period, he will receive his current base salary and may earn a pro‑rated 2026 cash bonus, subject to conditions including no termination for cause or breach of agreements. His existing equity awards will continue to vest through November 2, 2026, and the company states that his separation did not result from any disagreement over operations, policies, financial results, or accounting practices.
CONMED Corporation reported that it plans to exit its gastroenterology product lines as part of a broader portfolio optimization strategy. The Company announced that this change includes ending its distribution agreement with W.L. Gore & Associates, Inc. for the Gore® VIABIL® biliary stent, effective January 1, 2026, and it expects to exit the rest of its gastroenterology product portfolio as well.
The update was communicated through a press release dated December 5, 2025, which is furnished as an exhibit to this report. The announcement signals a strategic refocus on other parts of CONMED’s business, but the filing does not provide financial details about the gastroenterology products being exited.
CONMED Corporation furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1, dated November 5, 2025.
The company states the information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other Securities Act filings unless specifically referenced.
CONMED Corporation appointed Kim Kelderman to its Board of Directors effective September 8, 2025. He will serve on the Corporate Governance and Nominating Committee and the Strategy Committee, and the Board determined that he meets the independence requirements of the New York Stock Exchange and the company’s own standards.
Kelderman is currently President, Chief Executive Officer, and a director of Bio‑Techne, and previously held senior leadership roles at Thermo Fisher Scientific and Becton Dickinson. As a non‑employee director, he will receive the same annual cash and equity compensation as other non‑employee directors. Upon appointment, he received a prorated equity grant valued at approximately $134,766, consisting of 500 restricted stock units and stock options to purchase 6,227 shares of CONMED common stock at the September 8, 2025 closing price, vesting in full on September 8, 2026.
CONMED Corporation announced its Board declared a quarterly cash dividend of $0.20 per share. The dividend was declared on August 7, 2025 and is payable on October 3, 2025 to shareholders of record as of September 15, 2025. This is a cash distribution to owners of the company and represents a direct return of capital to shareholders for the quarter.
The current 8-K contains only the dividend declaration and payment details; it does not disclose earnings, changes to dividend policy, or other financial metrics. Investors seeking additional context on the company’s payout history or cash position will need to consult recent periodic reports or investor presentations.